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Fenning, Andrew, Glenn Harrison, Roselyn Rose’meyer, An-
drew Hoey, and Lindsay Brown. L-Arginine attenuates cardiovas-
cular impairment in DOCA-salt hypertensive rats. Am J Physiol Heart
Circ Physiol 289: H1408–H1416, 2005. First published May 27,
2005; doi:10.1152/ajpheart.00140.2005.—Nitric oxide (NO) is essen-
tial for normal function of the cardiovascular system. This study has
determined whether chronic administration of L-arginine, the biolog-
ical precursor of NO, attenuates the development of structural and
functional changes in hearts and blood vessels of deoxycorticosterone
acetate (DOCA)-salt hypertensive rats. Uninephrectomized rats
treated with DOCA (25 mg every 4th day sc) and 1% NaCl in the
drinking water for 4 wk were treated with L-arginine (5% in food,
3.4  0.3 g kg body wt1 day1). Changes in cardiovascular struc-
ture and function were determined by echocardiography, microelec-
trode studies, histology, and studies in isolated hearts and thoracic
aortic rings. DOCA-salt hypertensive rats developed hypertension,
left ventricular hypertrophy with increased left ventricular wall thick-
ness and decreased ventricular internal diameter, increased inflamma-
tory cell infiltration, increased ventricular interstitial and perivascular
collagen deposition, increased passive diastolic stiffness, prolonged
action potential duration, increased oxidative stress, and inability to
increase purine efflux in response to an increased workload. L-
Arginine markedly attenuated or prevented these changes and also
normalized the reduced efficacy of norepinephrine and acetylcholine
in isolated thoracic aortic rings of DOCA-salt hypertensive rats. This
study suggests that a functional NO deficit in blood vessels and heart
due to decreased NO synthase activity or increased release of reactive
oxygen species such as superoxide may be a key change initiating
many aspects of the cardiovascular impairment observed in DOCA-
salt hypertensive rats. These changes can be prevented or attenuated
by administration of L-arginine.
deoxycorticosterone acetate; oxidative stress; remodeling; collagen
NITRIC OXIDE (NO), essential for the proper functioning of the
cardiovascular system, is derived from L-arginine by NO syn-
thase in endothelial cells (35). NO synthase inhibition produces
hypertension, endothelial damage, cardiac hypertrophy, in-
flammation, atherosclerosis, ventricular contractile dysfunc-
tion, and fibrosis (20, 24, 31, 35). Many of these pathophysi-
ological responses are also characteristic of rat models of
mineralocorticoid hypertension such as the deoxycorticoste-
rone acetate (DOCA)-salt or aldosterone-salt hypertensive rat
(15), suggesting that decreased NO availability may be a
mechanism in these models. This possibility is supported by
the important role of decreased NO synthase activity in induc-
ing salt-sensitive hypertension in the Dahl rat (37, 42). Fur-
thermore, increased production of superoxide by NADPH
oxidase, which has been reported in aortic rings from DOCA-
salt hypertensive rats (11, 29, 41), would also decrease NO
availability, because superoxide reacts rapidly with NO, pro-
ducing peroxynitrite, possibly inducing further cellular dam-
age. Administration of L-arginine as a source of NO has been
shown to prevent severe nephrosclerosis, hypertension, hyper-
trophy, and collagen increases in aging spontaneously hyper-
tensive rats (SHR) (32, 40, 44), whereas L-arginine prevented
the development of hypertension in DOCA-salt hypertensive
rats (27).
The aim of this project was to determine whether oral
administration of L-arginine to DOCA-salt hypertensive rats
prevents or attenuates the development of structural and func-
tional changes in the heart and blood vessels. Structural
changes were characterized by histology and echocardiogra-
phy, whereas heart function was measured in vivo using
echocardiography and ex vivo in isolated perfused hearts.
Single-cell microelectrode recordings from left ventricular
papillary muscles were used to determine changes in cardiac
action potentials. Isolated thoracic aortic rings were used to
measure vascular reactivity.
METHODS
DOCA-Salt Hypertensive Rats
Male Wistar rats (8–10 wk old) were obtained from the Central
Animal Breeding House of The University of Queensland. All exper-
imental protocols were approved by the Animal Experimentation
Ethics Committee of The University of Queensland under the guide-
lines of the National Medical and Health Research Council of Aus-
tralia, which conform to the National Institutes of Health Guide for the
Care and Use of Laboratory Animals (NIH Publication No. 85-23,
revised 1996). All treated rats were uninephrectomized. The rats were
anesthetized with an intraperitoneal injection of tiletamine (25 mg/kg)
and zolazepam (25 mg/kg, Zoletil) together with xylazine (10 mg/kg,
Rompun); a lateral abdominal incision provided access to the kidney,
and the left renal vessels and ureter were ligated. The left kidney was
removed and weighed, and the incision site was sutured. Uninephrec-
tomized rats were given no further treatment or were given 1% NaCl in
the drinking water with subcutaneous injections of DOCA (25 mg in 0.4
ml of dimethylformamide every 4th day, DOCA-salt rats) (13). L-
Arginine was administered as a 5% mixture in powdered rat food, which
was available ad libitum for 28 days. Experiments were performed 28
days after surgery, as in previous studies (2, 9, 13, 27, 33).
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Assessment of Physiological Parameters
Food and water intake and body weights of all rats were measured
daily. Systolic blood pressure and heart rate were measured in selected
rats during light anesthesia [tiletamine (15 mg/kg ip) with zolazepam
(15 mg/kg ip)] using a tail pulse transducer (model MLT1010) and an
inflatable tail cuff with a Capto SP844 physiological pressure trans-
ducer (model MLT844/D) connected to a PowerLab data acquisition
unit (ADInstruments, Sydney, Australia). Rats were killed with an
injection of pentobarbitone sodium (200 mg/kg ip). Blood was taken
from the abdominal vena cava and centrifuged, and the plasma was
frozen. After the plasma was thawed, glucose was measured by
Precision Plus blood glucose electrodes (Medisense, Abbott Labora-
tories); plasma sodium and potassium concentrations were determined
by flame photometry; plasma malondialdehyde levels were deter-
mined by HPLC (43).
Echocardiography
Serial, in vivo left parasternal and left apical echocardiographic
images of rats were obtained with a 12-MHz-frequency fetal trans-
ducer (Hewlett-Packard Sonos 5500) at an image depth of 3 cm using
two focal zones (10). Rats were anesthetized as described for unine-
phrectomy. Left ventricular M-mode measurements at the level of the
papillary muscles included left ventricular end-diastolic dimensions,
left ventricular end-systolic dimensions, interventricular septum, and
posterior wall thicknesses and fractional shortening. Cardiac output,
ejection fraction, and left ventricular mass were derived from these
values (30). Pulsed-wave Doppler analyses of mitral valve inflows
were used as estimates of diastolic function.
Isolated Heart Preparations
The nonrecirculating heart preparation was used for isolated myo-
cardial experiments (9, 33). Briefly, after anesthesia with pentobarbi-
tone sodium (100 mg/kg ip) and administration of heparin (1,000 IU
iv) into the femoral vein, hearts were rapidly excised and placed in
ice-cold modified Krebs-Henseleit buffer containing (in mM) 119.1
NaCl, 4.75 KCl, 1.19 MgSO4, 1.19 KH2PO4, 25.0 NaHCO3, 11.0
glucose, and 2.16 CaCl2. Retrograde perfusion was initiated at con-
stant pressure (100 cmH2O) with modified Krebs-Henseleit buffer
maintained at 37°C and bubbled with 95% O2-5% CO2. A latex
balloon catheter was inserted into the left ventricle for measurement
of isovolumic function via connection to a Capto SP844 physiological
pressure transducer (model MLT844/D) linked to a PowerLab record-
ing system.
Diastolic stiffness. Myocardial diastolic stiffness was defined by
the stiffness constant (dimensionless), which is the slope of the linear
relation between the tangent elastic modulus (dyn/cm2) and stress
(dyn/cm2), as used in previous studies (9, 33). To assess contractile
function, maximal time derivative of pressure (dP/dt) was calculated
at a diastolic pressure of 10 mmHg. At the end of the experiment, the
atria were removed and the weight of the ventricles plus septum was
recorded.
Purine efflux. After equilibration, hearts were subjected to in-
creased cardiac workloads via bipolar atrial pacing for 5-min intervals
at 6 and 9 Hz (360 and 540 beats/min). Contractile function and
coronary venous effluent (from the cannulated pulmonary artery) were
sampled before and at 4 min into the 5-min pacing episodes (16).
Effluent samples were immediately frozen and stored at 80°C.
Samples were analyzed by reverse-phase HPLC on a Waters Alliance
HPLC using Waters Millenium software. Purines (adenosine, inosine,
and hypoxanthine) were eluted using a gradient comprising 50 mM
KH2PO4-3% methanol (buffer A) and 50% methanol-water (buffer B)
at a constant flow rate of 1 ml/min, and purine efflux was calculated
as nanomoles per minute per gram wet heart weight.
Cardiac energetics. Hearts were perfused with phosphate-free
modified Krebs-Henseleit perfusate and then placed inside a 20-mm
NMR tube and introduced into the center of a 56-mm-bore Oxford
400 (9.39-T) magnet (16). After 10 min of equilibration, acquisition of
5-min 31P NMR spectra (110 free induction decays) were acquired at
resting (unpaced) heart rate and during 15 min of normothermic
hypoxia (buffer gassed with 95% N2-5% CO2) and 30 min of reper-
fusion with normal buffer. Spectral intensities for phosphocreatine
(PCr), -ATP, and Pi were determined by computer integration using
resident VNMR software. Calculations of myocardial ATP and PCr
concentrations were performed as described previously (16).
Microelectrode Studies on Isolated Left Ventricular
Papillary Muscles
Rats were anesthetized by CO2 inhalation and then euthanized by
exsanguination. The thorax was opened quickly, and the heart was
removed. The left ventricular papillary muscles were quickly dis-
sected in cold Tyrode physiological salt solution (in mM: 136.9 NaCl,
5.4 KCl, 1.0 MgCl2 H2O, 0.4 NaH2PO4 2H2O, 22.6 NaHCO3, 1.8
CaCl2 2H2O, 5.5 glucose, 0.3 ascorbic acid, and 0.05 Na2EDTA)
bubbled with 95% O2-5% CO2. A stainless steel hook was placed in
one end of the papillary muscle. The muscle was placed in a 1.0-ml
experimental chamber continuously perfused with gassed warm (35
0.5°C) Tyrode solution at 3 ml/min and fixed at the other end with a
Table 1. Physiological parameters
UNX UNX  L-Arginine DOCA-Salt (4 wk) DOCA-Salt  L-Arginine
Systolic blood pressure, mmHg 1266 (14) 1316 (10) 1845*(14) 1392† (30)
Heart rate, beats/min 39011 (14) 3788 (10) 40618 (14) 36514† (30)
LV wt, mg/g body wt 2.060.04 (14) 2.110.03 (10) 3.350.05*(14) 2.790.04† (30)
RV wt, mg/g body wt 0.580.02 (14) 0.600.03 (10) 0.650.03*(14) 0.590.02† (30)
Kidney wt, mg/g body wt 4.960.14 (14) 5.030.31 (10) 11.030.29*(14) 9.490.41† (30)
TAR wall thickness, m 192.36.6 (6) 184.28.6 (6) 311.65.1*(6) 256.15.9† (6)
LV perivascular collagen fraction, %area 27.94.4 (6) 24.35.6 (6) 38.92.8*(6) 31.42.1† (6)
LV interstitial collagen fraction, %area 2.70.3 (6) 3.10.8 (6) 11.71.3*(6) 7.91.2† (6)
Diastolic stiffness 20.30.8 (10) 21.61.2 (12) 32.31.7*(10) 20.50.9† (12)
Maximum dP/dt, mmHg/s 1,760180 (10) 184090 (12) 1,380170*(10) 1,450160 (12)
Minimum dP/dt, mmHg/s 1,50080 (10) 1,55080 (12) 1,370170 (10) 1,320160 (12)
Blood glucose, mmol/l 10.30.9 (14) 10.51.4 (10) 11.30.7 (14) 11.00.3 (30)
Plasma Na, mmol/l 142.21.2 (14) 145.33.2 (10) 150.56.3 (14) 152.67.0 (30)
Plasma K, mmol/l 4.40.2 (14) 4.50.4 (10) 2.10.3*(14) 2.00.3*(30)
Plasma MDA, M 23.21.5 (9) 25.41.1 (10) 30.81.3*(10) 25.71.2† (10)
Values are means SE; number of experiments in parentheses. DOCA, deoxycorticosteronc acetate; dP/dt, time derivative of pressure; LV, left ventricle; RV,
right ventricle; TAR, thoracic aortic ring; MDA, malondialdehyde. *P  0.05 vs. UNX. †P  0.05 vs. DOCA-salt.
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small stainless steel pin embedded in a rubber base. The hook was
attached to a modified sensor element (SensoNor AE801) connected
to an amplifier (model TBM-4, World Precision Instruments). The
muscle was slowly (over 1 min) stretched to optimal preload. Con-
tractions were induced by field stimulation (Grass SD-9) via elec-
trodes on either side of the muscle (stimulation frequency  1 Hz,
pulse width  0.5 ms, stimulus strength  20% above threshold).
After maximum preload was attained, the muscle was allowed to
equilibrate for a further 45 min before impalement with a filamented
borosilicate glass microelectrode (1.5 mm OD; World Precision In-
struments) with a tip resistance of 5–15 m when filled with 3 M KCl.
The reference electrode was an Ag-AgCl electrode. An electrometer
(Cyto 721, World Precision Instruments) was used to record bioelec-
trical activity. All signals were recorded via a PowerLab 4S data
acquisition unit (ADInstruments). All preparations with a stable rest-
ing potential more negative than 60 mV were accepted. Continual
impalement throughout an experiment was not always possible; how-
ever, if displacement occurred, the results of a subsequent impalement
were accepted, provided the data fitted the criteria described above.
After a 20-min control period with microelectrode impalement, the
drug-free Tyrode solution perfusing the chamber was changed to a
solution containing 4-aminopyridine, and perfusion continued for a
further 25 min. Previous data obtained with Wistar rats indicated that
a maximum effect of 4-aminopyridine occurred after 20 min. Action
potential duration (APD) at 20%, 50%, and 90% of repolarization,
action potential amplitude, and action potential voltage over time
(dV/dtmax) were measured. Contractile parameters measured were
force of contraction and force of contraction over time (dF/dt).
Isolated Thoracic Aortic Rings
Thoracic aortic rings (	4 mm long) were suspended in Tyrode
solution at 35°C with a resting tension of 10 mN (8). Cumulative
concentration-response curves were performed for norepinephrine and
either acetylcholine or sodium nitroprusside in the presence of a
submaximal contraction to norepinephrine. Maximal contraction was
recorded as that produced by addition of a modified isotonic Tyrode
solution containing 100 mM KCl.
Collagen Distribution by Picrosirius Red Staining and Laser
Confocal Microscopy
The major organs were removed from all experimental animals and
then weighed. The left ventricle and septum underwent histological
analysis. Tissues were initially fixed for 3 days in Telly’s fixative (100
ml of 70% ethanol, 5 ml of glacial acetic acid, and 10 ml of 40%
formaldehyde) and then transferred into a prestain/fixative (modified
Bouin’s fluid: 85 ml of saturated picric acid, 5 ml of glacial acetic
acid, and 10 ml of 40% formaldehyde) for 2 days. The samples were
then dehydrated and embedded in paraffin wax. Thick sections (15
m) were cut and placed on glass slides coated with Mayer’s albumin
solution (1 g of powdered egg albumin, 50 ml of glycerol, and 50 ml
of distilled water), left to air dry for 2 days, and then heated in an oven
at 56°C for 1 h. Phosphomolybdic acid (0.2% in distilled water, 5 min)
was applied to reduce nonspecific binding of the stain to the section,
and the slides were washed in distilled water. The slides were stained
with collagen-selective picrosirius red (0.1% sirius red F3BA in
saturated picric acid) and allowed to incubate for 90 min. The sections
were washed, dehydrated, and mounted in Depex, and a coverslip was
applied. The stained sections were analyzed on a laser scanning
confocal microscope (model MRC-1024, Bio-Rad) with a rhodamine-
Texas red filter (emission at 568 nm and green excitation at 609 nm,
DF 32). Randomly assigned slides and sections representing the
perivascular areas of the left ventricle were scanned. The images were
taken with a 
40 objective lens and analyzed for pixel intensity in a
specified area of the section. The data were compiled by a software
image-rendering program (IA-IP-Lab, Scanalytics, Australia).
Inflammatory cells were observed after hematoxylin and eosin
staining of 5-m-thick sections of left ventricle. Slides were visual-
ized under a standard light microscope initially at 
450 magnifica-
tion, and the tissue was scanned to gain an overall indication of
inflammatory cell infiltration. Once areas of inflammation were iden-
tified, 
1,000 magnification was used to confirm and identify inflam-
matory cells.
Fig. 1. Daily water intake measurements for uninephrectomized rats (UNX),
uninephrectomized rats treated with L-arginine (UNX  L-Arg), deoxycorti-
costerone acetate (DOCA)-salt hypertensive rats (DS), and DOCA-salt hyper-
tensive rats treated with L-arginine (DS  L-Arg). *P  0.05 vs. UNX.
Fig. 2. Daily body weight measurements for uninephrectomized rats, unine-
phrectomized rats treated with L-Arg, DOCA-salt hypertensive rats, and
DOCA-salt hypertensive rats treated with L-Arg. *P  0.05 vs. UNX.
Fig. 3. Daily dose of L-arginine administered to uninephrectomized and
DOCA-salt hypertensive rats.
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Data Analysis
Values are means  SE. The results were analyzed by one-way
ANOVA with post hoc comparisons of group means via unpaired or
paired t-tests as appropriate. P  0.05 was considered significant.
Drugs
DOCA, L-arginine, heparin, norepinephrine, acetylcholine, and
sodium nitroprusside were purchased from Sigma Chemical (St.
Louis, MO). L-Arginine was thoroughly mixed with ground rat food
pellets to a final concentration of 5%. Norepinephrine, acetylcholine,
and sodium nitroprusside were dissolved in distilled water; 4-amino-
pyridine was dissolved in 0.01 M HCl; DOCA was dissolved in
dimethylformamide with mild heating.
RESULTS
DOCA-salt hypertensive uninephrectomized rats developed
hypertension (Table 1) and an increased water intake (Fig. 1)
but failed to significantly gain weight (Fig. 2). L-Arginine
significantly prevented the increase in systolic blood pressure
in DOCA-salt hypertensive rats (Table 1) but failed to alter
body weight or water intake (Figs. 1 and 2). DOCA-salt
hypertension significantly reduced plasma potassium concen-
trations but did not alter plasma glucose and sodium concen-
trations; oral L-arginine treatment did not alter these parameters
(Table 1). Plasma malondialdehyde concentrations, as a mea-
sure of oxidative stress, were increased after 4 wk of DOCA-
salt hypertension; this increase was prevented by L-arginine
treatment (Table 1). Intake of L-arginine, calculated from the
daily food intake, was not significantly different between the
treated groups: 3.6 0.1 and 3.4 0.3 g kg body wt1 day1
in uninephrectomized rats treated with L-arginine and DOCA-
salt rats treated with L-arginine, respectively (Fig. 3).
Hearts from DOCA-salt rats showed marked cardiac hyper-
trophy, as evidenced by left ventricular wet weight relative to
body weight and left ventricular mass derived from echocar-
diography (Tables 1 and 2). This was associated with a 21%
decrease in left ventricular internal diameter, indicating con-
centric cardiac hypertrophy (Table 2). Additionally, the rela-
tive wet weights of the right ventricle and the remnant kidney
from DOCA-salt rats were increased (Table 1). Treatment with
L-arginine for 28 days attenuated the increased organ weights
of both ventricles and kidney and reduced the decrease in left
ventricular chamber diameter (Tables 1 and 2).
The left ventricle of DOCA-salt rats showed marked inflam-
matory cell infiltration perivascularly, in scar tissue, and through-
out the interstitium compared with uninephrectomized rats or
uninephrectomized rats treated with L-arginine. Scar tissue also
contained many inflammatory cells in L-arginine-treated DOCA-
salt rats, but there were fewer sites of scarring in the L-arginine-
treated rats. In addition, interstitial tissue showed fewer inflam-
matory cells in DOCA-salt rats treated with L-arginine. The left
ventricles from DOCA-salt rats showed a significant increase in
collagen, particularly interstitial collagen content, which was par-
tially prevented by administration of L-arginine (Table 1, Fig. 4).
Functionally, diastolic stiffness obtained from the isolated Lange-
ndorff-perfused heart preparation in DOCA-salt rats was signifi-
cantly increased (Table 1). This increase was prevented by oral
L-arginine treatment (Table 1). Furthermore, thoracic aortic wall
thicknesses and aortic blood flow velocities were increased by
DOCA-salt treatment; L-arginine prevented these vascular
changes (Tables 1 and 2).
Echocardiographic assessment of heart function showed that
L-arginine failed to alter the increased ejection fraction and
decreased cardiac output observed in DOCA-salt rats (Table
2). The lack of significant improvement in systolic function by
L-arginine in vivo was supported by contractility studies on
isolated Langendorff-perfused hearts. Hearts from DOCA-salt
Fig. 4. Representative photomicrographs of collagen distribution visualized by picrosirius red staining in the left ventricle of uninephrectomized rats (A),
DOCA-salt hypertensive rats (B), and DOCA-salt hypertensive rats treated with L-Arg (C).
Table 2. Cardiac function assessed by echocardiography
UNX
(n  10)
UNX 
L-Arginine
(n  8)
DOCA-Salt
(4 wk)
(n  10)
DOCA-
Salt  L-
Arginine
(n  10)
LVIDd, mm 6.690.18 7.240.12 5.510.37* 6.410.17†
LVPWd, mm 1.740.17 1.840.04 1.980.09 1.800.12
E/A 1.920.02 1.830.07 1.640.10* 1.810.14†
Ejection fraction, % 83.14.4 85.61.8 92.71.2* 92.92.1*
Cardiac output, ml/min 75.33.6 82.43.8 53.76.7* 51.93.1*
Ascending aorta, m/s 0.750.08 0.810.03 1.230.05* 0.920.07†
LV mass, g 0.760.04 0.770.02 1.360.09* 0.790.06†
Values are means  SE; n, number of experiments. LVIDd, LV internal
diameter in diastole; LVPWd, LV posterior wall thickness in diastole; E/A,
mitral valve flow rate ratio. *P  0.05 vs. UNX. †P  0.05 vs. DOCA-salt.
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rats showed a decreased dP/dt that was unaltered by L-
arginine treatment (Table 1). The decreased mitral valve flow
rate ratio indicated a restrictive filling pattern that was pre-
vented by L-arginine treatment (Table 2).
In hearts from DOCA-salt rats, APD was markedly in-
creased at 20%, 50%, and 90% of repolarization; L-arginine
prevented prolongation at 20% and 90% repolarization (Fig. 5).
However, when challenged by 4-aminopyridine, L-arginine
failed to maintain normalization of the resultant increases in
APD from that of DOCA-salt-treated myocytes (Fig. 5). No
changes in the resting membrane potential were evident be-
tween any of the four groups (data not shown).
Fig. 5. Representative action potentials (A) and action potential duration at 20%, 50%, and 90% repolarization (B–D) from single-cell cardiac microelectrode
recordings taken at an initial time point and after equilibrium response to 1 and 5 mM 4-aminopyridine (4-AP) for uninephrectomized rats (n  8),
uninephrectomized rats treated with L-Arg (n  8), DOCA-salt hypertensive rats (n  12), and DOCA-salt hypertensive rats treated with L-Arg (n  12).
*P  0.05 vs. UNX.
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DOCA-salt hypertension caused decreased contractile re-
sponses to norepinephrine and clear endothelial dysfunction,
shown as minimal relaxation responses to acetylcholine in
isolated sections of thoracic aortic rings (Fig. 6, A and B).
These changes were accompanied by unaltered responses to
sodium nitroprusside across all treatment groups (Fig. 6C).
Treatment with oral L-arginine normalized these decreased
responses (Fig. 6, A and B).
Assessment of metabolic status of hearts using 31P NMR
spectroscopy in response to hypoxia-reperfusion showed that
L-arginine increased metabolic status at rest (increased ATP
and PCr) compared with uninephrectomized and DOCA-salt
rats (Table 3). Hypoxia led to a rapid reduction in contractile
function and high-energy phosphates, and there was no differ-
ence in the rate of fall of ATP, PCr, or pH between groups
during hypoxia (results not shown). Normoxic reperfusion
quickly restored metabolite levels in all groups; however,
L-arginine-treated hearts again recovered to higher levels con-
sistent with prehypoxic values that were mirrored by higher
coronary flow rates.
Purine efflux from isolated Langendorff-perfused hearts was
used as an indicator of metabolic efficiency (ATP breakdown)
in response to increased workload. An increase in heart rate
from 360 to 540 beats/min produced an increase in purine
efflux in uninephrectomized hearts from 0.76  0.29 to 1.3 
0.34 nmol min1 g tissue1, an increase of 76  9%. In
contrast, hearts from DOCA-salt rats displayed a much smaller
increase in purine release in response to increased workload
(from 0.35  0.18 to 0.45  0.12 nmol min1 g tissue1, an
increase of 17  13%), suggesting an inability to produce or
utilize ATP. L-Arginine increased the purine release in hearts
from DOCA-salt rats (from 0.41  0.15 to 1.04  0.25
nmol min1 g tissue1, an increase of 74  23%), results
similar to uninephrectomized hearts, suggesting improved
functional and metabolic capacity in response to an increased
workload.
DISCUSSION
Cardiovascular damage and impairment of function in hu-
mans as a result of hypertension can be mimicked by rat
models of hypertension such as the DOCA-salt hypertensive
rat (14, 15). In this study, the structural and functional changes
in DOCA-salt hypertensive rats included left ventricular hy-
pertrophy with an increased left ventricular wall thickness and
decreased ventricular internal diameter, increased inflamma-
tory cell infiltration, increased ventricular interstitial and
perivascular collagen deposition, increased passive diastolic
stiffness, prolonged APD, increased oxidative stress, and in-
ability to increase purine efflux in response to an increased
workload. Administration of L-arginine markedly attenuated or
prevented these structural and functional changes. L-Arginine
also normalized the reduced efficacy of norepinephrine and
acetylcholine in isolated thoracic aortic rings of DOCA-salt
hypertensive rats.
L-Arginine, as substrate for NO synthase, is the precursor of
the short-acting paracrine vasodilator NO (35). Selective inhi-
bition of NO synthase by compounds such as nitro-L-arginine
methyl ester induces hypertension (3, 28, 35). Salt-sensitive
hypertension may result from dysregulation of the L-argi-
nine-NO system (37, 42). In Dahl salt-sensitive rats, where a
high-salt diet induces hypertension within 2–8 wk, a marked
downregulation of inducible NO synthase was shown in ani-
mals fed a regular diet with further reductions in animals fed a
high-salt diet (37). L-Arginine prevented the increase in blood
pressure in salt-sensitive Dahl rats fed a high-salt diet (42).
L-Arginine administration up to 3 g kg1 day1 also pre-
vented the development of hypertension in DOCA-salt hyper-
tensive rats (1, 27). Our results showed that a similar dose of
Fig. 6. Cumulative concentration-response curves for norepinephrine (A),
acetylcholine (B), and sodium nitroprusside (C) in thoracic aortic rings from
uninephrectomized rats, uninephrectomized rats treated with L-Arg, DOCA-
salt hypertensive rats, and DOCA-salt hypertensive rats treated with L-Arg.
*P  0.05 vs. UNX. **P  0.05 vs. DS.
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L-arginine markedly attenuated the increase in blood pressure
in DOCA-salt rats, strongly indicating that a decreased
availability of NO plays a key role in the development of
hypertension in the DOCA-salt model, as in the Dahl salt-
sensitive rat.
NO is rapidly removed by reaction with superoxide to form
the very reactive free radical peroxynitrite. Aortic rings from
DOCA-salt hypertensive rats showed an increased production
of superoxide by NADPH oxidase (11, 29, 41). This was
confirmed in our study by the increased plasma malondialde-
hyde concentrations that were reduced in L-arginine-treated
rats. Thus the decreased NO availability in DOCA-salt rats
could also be a result of this increased oxidative stress in this
model of hypertension; L-arginine, by increasing NO produc-
tion, reduced this stress and any subsequent damage. This
finding is consistent with results showing that a reduction in
aortic superoxide production in DOCA-salt hypertensive rats
by administration of sesamin, a lignan from sesame oil, was
associated with a lowered systolic blood pressure and reduced
impairment of endothelium-dependent vascular relaxation (36).
Although treatment with L-arginine markedly attenuated
hypertension in these rats, ventricular hypertrophy was reduced
to a lesser extent. In DOCA-salt hypertensive rats, endothelin
acting predominantly via endothelin type A receptors is the
most likely candidate as the mediator of hypertrophy, because
selective antagonism of the endothelin type A receptors pre-
vented further ventricular hypertrophy in several rat models of
hypertension, including the DOCA-salt hypertensive rat (2);
this mechanism is likely to be unaffected by increased NO
concentrations.
The prevention of an excessive deposition of extracellular
matrix proteins in the heart, termed cardiac fibrosis, has been
studied largely in rat models, because fibrosis is a process that
is inherently difficult to study in normal human patients.
Excessive collagen deposition, principally collagens I and III
in the heart, impairs the ability of the ventricle to relax
(diastolic dysfunction) and also increases the risk of cardiac
arrhythmias (4). Cardiac fibrosis has been defined as reactive
(interstitial and perivascular fibrosis) or reparative (scarring
following necrosis) (45); both types occur in the heart of the
DOCA-salt hypertensive rat (6, 46). Inhibition of the renin-
angiotensin-aldosterone system with the angiotensin-convert-
ing enzyme inhibitor captopril, the AT1 receptor antagonist
candesartan, or the aldosterone antagonist spironolactone (9) or
with the anti-inflammatory compound pirfenidone (33) re-
versed the reactive fibrosis in DOCA-salt hypertensive rats.
Because inflammation may play an important role in cardiac
fibrosis (18, 38), the decreased collagen deposition may be a
consequence of the decreased inflammatory cell infiltration in
the interstitium and scar tissue. Suppression of infiltration of
inflammatory cells (monocyte/macrophages) and myocardial
fibrosis has been shown with tranilast in DOCA-salt hyperten-
sive rats (19). In several models of chronic renal damage,
L-arginine reversed macrophage infiltration, blunted increases
in interstitial volume and collagen IV, and decreased protein-
uria (23). In aged SHR rats, chronic L-arginine administration
reversed severe nephrosclerosis (40). Fibrosis may be strongly
linked to a lack of NO initiating an inflammatory response. The
NO-deficient nitro-L-arginine methyl ester model is character-
ized by a malignant inflammatory response leading to perivas-
cular and cardiac fibrosis (26). Our results suggest that an NO
deficiency may represent the key process leading to inflamma-
tory cell infiltration and excessive collagen deposition during
DOCA-salt hypertension.
The complexity of collagen synthesis and degradation pro-
vides several points of attack for pharmacological therapy to
prevent deposition of collagens (7). The precise mechanisms
underlying the observed reduction in collagen deposition in
DOCA-salt hypertensive rats observed after L-arginine treat-
ment are not known. Compounds that release NO, for example,
bradykinin, decreased cardiac fibroblast function to decrease
collagen expression, probably by increasing intracellular
cGMP concentrations (21). In addition, the NO donor diethyl-
enetriamine NONOate (100 M), but not bradykinin, de-
creased proliferation of fibroblasts (25). In cultured rabbit
vascular smooth muscle cells, NO-generating compounds such
as S-nitroso-N-acetyl-penicillamine and sodium nitroprusside
showed reversible, hemoglobin-sensitive inhibition of collagen
synthesis, implicating NO release (25). Thus NO from the
endothelium may inhibit local collagen production in the heart
and blood vessels. Furthermore, the formation of plasminogen
activator inhibitor-1, an inhibitor of matrix degradation, is
suppressed by NO (5, 17).
The observed changes after L-arginine treatment (attenuation
of blood pressure increase and fibrosis) are only relevant if
cardiac function can be shown to be improved by this inter-
vention. Echocardiographic measurement of wall thickness in
L-arginine-treated DOCA-salt rats confirmed the results of
heart weight measurements, i.e., minimal improvements with
L-arginine treatment. However, L-arginine prevented the nar-
rowing of the internal ventricular diameter that characterizes
the DOCA-salt rat. This should improve diastolic filling and
allow efficient cardiac contraction and expulsion of blood, as
shown by the maintained cardiac output. The metabolic status
of the myocardium of DOCA-salt rats was markedly improved
by L-arginine supplementation, as shown by the improved
response to workload stress imposed by pacing and hypoxia.
Purine efflux during increased workloads in L-arginine-treated
Table 3. 31P NMR-derived metabolite concentrations during hypoxia-reperfusion in isolated hearts
Reperfusion
Prehypoxia 15 min Hypoxia 10 min 30 min
ATP, mmol/l PCr, mmol/l
ATP,
mmol/l PCr, mmol/l ATP, mmol/l PCr, mmol/l ATP, mmol/l
PCr,
mmol/l
UNX (4 wk) 9.60.3 16.02.8 6.61.8 12.13.4 7.92.4 20.82.6 7.32.2 22.03.0
DOCA-salt (4 wk) 9.20.5 16.51.0 9.01.3 7.41.6 7.41.4 18.11.4 7.01.4 18.71.5
DOCA-salt  L-Arg (4 wk) 10.90.6* 20.41.5* 5.70.7 9.12.6 10.91.8* 23.12.3* 11.81.6* 222.3
Values are means  SE. PCr, phosphocreatine. *P  0.05 vs. DOCA-salt.
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hearts returned to the normal levels seen in hearts from unine-
phrectomized rats. L-Arginine increased high-energy phos-
phate levels at rest above that seen in hearts from uninephrec-
tomized and DOCA-salt rats, and these elevated concentrations
were evident after hypoxia aided by improved coronary flow.
An increased release of NO during exercise has been proposed
to provide the heart with improved blood flow and metabolite
delivery (22); L-arginine treatment may be providing this
increase in NO in NO-deficient hearts from DOCA-salt rats.
The increased collagen deposition in hearts from DOCA-salt
rats was associated with an increased diastolic stiffness, as
measured in the isolated perfused Langendorff-perfused heart
preparation. The relation between collagen deposition and
stiffness is very complex: in the SHR heart, stiffness is corre-
lated with the degree of cross-linking, rather than the total
collagen content (39), and the alignment of fibers is probably
also relevant. Importantly, L-arginine totally prevented the
increase in diastolic stiffness. This observation clearly shows
that the decrease in fibrosis in L-arginine-treated DOCA-salt
rats has functional significance and that the L-arginine-NO
system plays an integral role in the pathogenesis of diastolic
dysfunction. Our previous studies showed that the increased
passive stiffness in DOCA-salt hypertensive rats can be atten-
uated or reversed by inhibition of the renin-angiotensin system
by captopril, candesartan, or spironolactone or by other com-
pounds such as pirfenidone or amiloride (9, 33).
Cardiac hypertrophy and excess collagen deposition are
linked closely with cardiac dysfunction and ventricular ar-
rhythmias (4). The incidence of arrhythmias in compensated
cardiac hypertrophy is related to fibrosis and the changes in
membrane proteins linked to cardiac hypertrophy and fibrosis
(4). It has been shown in SHR rats that hypertension-induced
fibrosis leads to fatal ventricular arrhythmias (4). Additionally,
in DOCA-salt rats, hypertrophy directly prolonged APD as a
result of a large reduction in the early transient outward
potassium channel currents (34) after downregulation of K
channel expression (12). L-Arginine treatment of DOCA-salt
rats prevented the resting prolongation in APD observed in
tissues from DOCA-salt rats, suggesting normalization of the
early transient outward current, which should in turn increase
susceptibility to inhibition by 4-aminopyridine, an effect that
was observed. Therefore, NO supplementation elicits a protec-
tive response to electrical activity in hearts from DOCA-salt
rats directly by restoring the early transient outward current
and/or indirectly by reducing hypertrophy and fibrosis.
In summary, many of the cardiac and vascular changes
observed in the DOCA-salt rat can be prevented or attenuated
by treatment with L-arginine. This suggests that a functional
NO deficit in blood vessels and the heart due to decreased NO
synthase activity or increased release of reactive oxygen spe-
cies such as superoxide may be a key change initiating many of
these cardiovascular impairments.
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